Astrazeneca stock down 1.17% despite positive earnings outlook

From Nasdaq: 2025-06-16 18:15:00

Astrazeneca (AZN) closed at $73.55, down 1.17% from the previous day, lagging behind S&P 500’s gain of 0.94%. Shares had risen 8.15% in the past month. Analysts expect earnings to rise 12.12% to $1.11 per share and revenue to increase by 8.42% to $14.03 billion in the upcoming earnings report.

Astrazeneca’s stock projections show a positive outlook with expectations of a 9.25% rise in earnings to $4.49 per share and a 6.67% increase in revenue to $57.68 billion for the year. Analysts believe positive estimate revisions are a good sign for the business outlook and can impact share price momentum.

With a Zacks Rank of #3 (Hold), Astrazeneca’s Forward P/E ratio of 16.56 is below the industry average of 19.72. The PEG ratio of 1.36 indicates potential growth. The Medical – Biomedical and Genetics industry ranks in the top 32% of all industries, with a Zacks Industry Rank of 78.

Zacks Research Chief highlights a little-known satellite-based communications firm as a top pick with potential to double its stock value. The industry’s growth potential and increasing customer base position this company for significant revenue growth. Analysts forecast a major revenue breakout in 2025, offering a promising investment opportunity to investors.



Read more at Nasdaq: Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know